Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Sort by Random

Display 15 Products per page

Orthobiologics for Musculoskeletal Soft Tissue Replacement and Regeneration

$4,750.00

This medical market and technology report provides a comprehensive discussion of the global market for orthobiologics for musculoskeletal soft tissue replacement and regeneration (including cell-based therapies and tissue scaffolds and grafts). Geographic markets covered by this analysis include the US, Japan, five major EU markets (France, Germany, Italy, Spain, and the UK), and the Rest of World (RoW), which includes all other countries.
October 11, 2019
Find out more
Chronic Lymphocytic Leukemia (CLL) KOL Interview – Germany

$599.00

A Germany-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for CLL. Pipeline therapies discussed include Brukinsa, U2 regimen, non-covalent BTK inhibitors, and CD19-directed CAR-T therapy.
March 17, 2022
Find out more
Market Spotlight: Cutaneous T-Cell Lymphoma (CTCL)

$1,318.00

This Market Spotlight report covers the Cutaneous T-Cell Lymphoma (CTCL) market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, recent events and analyst opinion, probability of success, a 10-year disease incidence and prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
February 1, 2022
Find out more
Ganetespib
Read More
Ganetespib, under development by Synta, is a small molecule inhibitor of HSP90. HSP90 is a chaperone protein required to drive growth, proliferation, and cell survival in tumor tissue.
September 17, 2015
Find out more
Disease Analysis: Chronic Myeloid Leukemia (CML)
Read More
Chronic myeloid leukemia (CML) is defined as a cancer of the blood in which a mutation in myeloid hematopoietic stem cells causes the overproduction of immature and dysfunctional white blood cells (myeloblasts, also known as blasts), preventing the normal production and function of healthy white blood cells, red blood cells, and platelets.
February 25, 2022
Find out more
2015 Breast Cancer Pulse #1

$599.00

This five-question survey of oncologists focuses on treatments for metastatic or locally advanced, HR+/HER2- breast cancer.
May 13, 2015
Find out more
Aricept
Read More
Aricept (donepezil; Eisai/Pfizer) has been the gold standard in the treatment of all stages of
Alzheimer’s disease for more than a decade.
September 2, 2016
Find out more
Disease Analysis: HER2+ Breast Cancer
Read More
Amplification of the HER2/neu oncogene and related genetic elements on chromosome 17 increases HER2 expression and accelerates tumorigenesis. The natural disease progression meant that, historically, women with breast cancer who overexpressed HER2 were found to have significantly shorter disease-free survival and overall survival compared with women without HER2 amplification; however, the introduction of trastuzumab in 1998 drastically changed patient outcomes, to the point where HER2+ breast cancer patients now have the longest median survival of all breast cancer subtypes. HER2 is overexpressed in approximately 20% of breast cancers.
May 20, 2022
Find out more
Joint Replacement Implants

$4,750.00

The global market for joint replacement implants, which includes prostheses for the hips, knees, shoulders, elbows, ankles, and small joints, totaled nearly $16.4bn in 2017. This market is projected to increase at a compound annual growth rate of 3.8%, reaching nearly $19.8bn in 2022.
July 31, 2018
Find out more
Oncology Pathways in the US – Friend or Foe for Pharma

$7,500.00

This strategy report focuses on Oncology Pathways in the US including management of oncology costs, oncology clinical pathway programs and developers, impact of pathways on oncology, and the future of oncology pathways.
July 31, 2015
Find out more
Epidiolex
Read More
GW Pharmaceuticals is developing Epidiolex, a first-in-class cannabinoid drug for the treatment of

childhood seizures.
May 23, 2017
Find out more
Vectibix
Read More
Vectibix (panitumumab; Amgen/Takeda) is a fully human immunoglobulin G2 monoclonal antibody that binds to the extracellular domain of the epidermal growth factor receptor (EGFR).
December 11, 2017
Find out more
Spain, Surgical Procedure Volumes

$4,850.00

This report presents an overview of selected medical specialties and the number of surgical procedures performed for selected diseases/disorders in the European Union country of Spain.
November 1, 2013
Find out more
Lidoderm
Read More
Lidoderm is a medicated plaster containing 5% lidocaine, and was developed by Endo Pharmaceuticals. Lidocaine is an amide-type local anesthetic agent that acts by stabilizing neuronal membranes.
May 31, 2018
Find out more
Sotagliflozin
Read More
Sotagliflozin (Lexicon/Sanofi) is an orally administered drug currently being investigated for the treatment of type 1 and type 2 diabetes. It is a dual inhibitor of the sodium-glucose cotransporter-1 (SGLT-1) and SGLT-2 transporters.
November 7, 2017
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Call Back

Name

Email *

Company name *

Phone number *